Infiltrating breast cancer in women younger than 25 years: 13 Cases;Cancer du sein infiltrant chez les femmes de moins de 25 ans: À propos de 13 cas

Presse Medicale

Volumn 35, Issue 11 I, 2006, Pages 1618-1624

  Paillocher, Nicolas ^a   Lacourtoisie, Sophie Abadie ^b   Fondrinier, Eric ^b   Catala, Laurent ^a   Morand, Clothilde ^b   Boursier, Jérôme ^a   Guerin, Olivier ^b   Descamps, Philippe ^a  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b CENTRE PAUL PAPIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HORMONE RECEPTOR;

ADULT; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER GRADING; CANCER INFILTRATION; CANCER INVASION; CLINICAL ARTICLE; CLINICAL EXAMINATION; DISEASE SEVERITY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; PROGNOSIS; RETROSPECTIVE STUDY;

EID: 33750718495     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0755-4982(06)74869-2     Document Type: Article

References (33)

1. Osteen RT, Cady B, Chmiel JS, Clive RE, Doggett RL, Friedman MA et al. 1991 national survey of carcinoma of the breast by the Commission on Cancer. J Am Coll Surg. 1994; 178(3): 213-9.
2. Kollias J, Elston CW, Ellis IO, Robertson JF, Blamey RW. Early-onset breast cancer-histopathological and prognostic considerations. Br J Cancer. 1997; 75(9): 1318-23.
3. UK National Statistics office.
4. Kothari A S, Beechey-Newman N, D'Arrigo C, Hanby AM, Ryder K, Named H et al. Breast carcinoma in women age 25 years or less. Cancer 2002; 94: 606-14.
5. Kaplan E, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
6. McCormick B. Selection criteria for breast conservation. The impact of young and old age and collagen vascular disease. Cancer. 1994; 74(Suppl): 430-5.
7. Gloeckler Ries L, Pollack ES, Young JL. Cancer patient survival : surveillance, epidemiology, and end results program, 1973-79. J Natl Cancer Inst. 1983; 70: 693-707.
8. Chung M, Chang H R, Bland K I, Wanebo HJ. Younger women with breast carcinoma have a poorer prognosis than older women. Cancer 1996; 77: 97-103.
9. Bonnier P, Romain S, Charpin C Lejeune C, Tubiana N, Martin PM et al. Age as a prognostic factor in breast cancer: relationship to pathologic and biologic features. Int J Cancer 1995; 62: 138-44.
10. Han W, Kim SW, Park IA, Kang D, Kim SW, Youn YK et al. Young age: an independent risk factor for disease-free survival in women with operable breast cancer. 2004; 4: 82.
11. Lannin DR, Harris RP, Swanson FH, Edwards MS, Swanson MS, Pories WJ. Difficulties in diagnosis of carcinoma of the breast in patients less than fifty years of age. Surg Gynecol Obstet. 1993; 177(5): 457-62.
12. Sidoni A, Cavaliere A, Bellezza G, Scheibel M, Bucciarelli E. Breast cancer in young women: clinicopathological features and biological specificity. Breast. 2003; 12(4): 247-50.
13. Walker RA, Gullick WJ, Varley JM. An evaluation of immunoreactivity for c-erbB-2 protein as a marker of poor short-term prognosis in breast cancer. Br J Cancer. 1989; 60(3): 426-9.
14. Kim SH, Simkovich-Heerdt A, Tran KN, Maclean B, Borgen PI. Women 35 years of age or younger have higher locoregional relapse rates after undergoing breast conservation therapy. J Am Coll Surg. 1998; 187(1): 1-8.
15. Albain KS, Allred DC, Clark GM. Breast cancer outcome and predictors of outcome: are there age differentials? J Natl Cancer Inst Monogr. 1994; 16: 35-42.
16. Bertheau P, Steinberg SM, Cowan K, Merino MJ. Breast cancer in young women: clinicopathologic correlation. Semin Diagn Pathol 1999; 16: 248-56.
17. Fisher CJ, Egan MK, Smith P, Wicks K, Millis RR, Fentiman IS. Histopathology of breast cancer in relation to age. Br J Cancer. 1997; 75(4): 593-6.
18. Nemoto T, Vana J, Bedwani RN, Baker HW, McGregor FH, Murphy GP. Management and survival of female breast cancer: results of a national survey by the American College of Surgeons. Cancer. 1980; 45(12): 2917-24.
19. Rasmussen BB, Rose C, Thorpe SM, Hou-Jensen K, Daehnfeldt JL, Palshof T. Histopathological characteristics and oestrogen receptor content in primary breast carcinoma. Virchows Arch. Pathol. Anat. 1981; 390(3): 347-51.
20. Gonzales-Angulo AM, Broglio K, Kau SW, Eralp Y, Erlichman J, Valero V et al. Woman age less than 35 years with primary breast carcinoma: disease features and presentation. 2005; 103(12): 2466-72.
21. Walker RA, Gullick WJ, Varley JM. An evaluation of immunoreactivity for c-erbB-2 protein as a marker of poor short-term prognosis in breast cancer. Br J Cancer. 1989; 60(3): 426-9.
22. Allred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ, Gilchrist KW et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol. 1992; 23(9): 974-9.
23. Xiong Q, Valero V, Kau V, Taylor S, Smith TL, Buzdar AU et al. Female patients with breast carcinoma age 30 years and younger have a poor prognosis. The M.D. Anderson Cancer Center experience. Cancer. 2001; 92: 2523-8.
24. Giacalone PL, Roger P, Dubon O, El Gareh N, Daures JP, Laffargue F. Traitement conservateur des cancers du sein : zonectomie vs oncoplastie. Étude prospective à propos de 99 cas. Annales de chirurgie. 2006; 131: 256-61
25. Kroman N, Jensen MB, Wohlfahrt J, Mouridsen HT, Andersen PK, Melbye M. Factors influencing the effect of age on prognosis in breast cancer: population based study. BMJ. 2000; 320(7233): 474-8.
26. Jayasinghe UW, Taylor R, Boages J. Is age at diagnosis an independent pronostic factor for survival following breast cancer? ANZ J Surg. 2005; 75(9): 762-7.
27. Early breast cancer trialist's collaborative group. Tamoxifen for early breast cancer. On overview of the randomised trials. Lancet. 1998; 351: 1451-67.
28. Early breast cancer trialist's collaborative group. Ovarian ablation in early breast cancer: overview of the randomized trials. Lancet. 1996; 348: 1189-96.
29. Davidson NE, O'Neil A, Vukov A, Osborne CK, Martino S, White DR, Abeloff MD et al. Chemoendocrine therapy for premenopausal women with axillary lymphnode-positive, steroid hormone receptor-positive breast cancer: results from INT0101 (E5188). J Clin Oncol. 2005; 23: 5869-72.
30. Taylor CW, Grenn S, Dalton WS, Martino S, Rector D, Ingle JN et al. Multicenter randomised clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J Clinical Oncol. 1998; 16: 994-9.
31. Boccardo F, Rubagotti A, Perotta A. Amoroso D, Balestrero M, De Matteis A et al. Ovarian ablation versus goserelin with or without tamoxifen in pre-menopausal patients with advanced breast cancer; results of a multicentric Italian study. Ann Oncol. 1994; 5: 337.
32. Burnstein HJ, Winer EP. Primary care for survivors of breast cancer. NEJM. 2000; 343(15): 1086-94.
33. Mignot L, Morvan F, Berdah J Querleu D, Laurent JC, Verhaeghe M et al. Grossesses après cancer du sein traité. Résultats d'une étude cas-témoins. Presse Med. 1986; 15: 1961-4.